{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:54:45Z","timestamp":1788195285128,"version":"build-2803163510"},"reference-count":20,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81830008"],"award-info":[{"award-number":["81830008"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81630006"],"award-info":[{"award-number":["81630006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873427"],"award-info":[{"award-number":["81873427"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0790-y","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T17:37:25Z","timestamp":1575913045000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma"],"prefix":"10.1136","volume":"7","author":[{"given":"Jia","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6838-3955","authenticated-orcid":false,"given":"Fankai","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"issue":"5","key":"790_CR1","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/bjh.15412","volume":"182","author":"C Gisselbrecht","year":"2018","unstructured":"Gisselbrecht C, Van Den Neste E. How I manage patients with relapsed\/refractory diffuse large B cell lymphoma. Br J Haematol. 2018;182(5):633\u201343.","journal-title":"Br J Haematol"},{"issue":"8","key":"790_CR2","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3324\/haematol.2017.168401","volume":"103","author":"M Trneny","year":"2018","unstructured":"Trneny M, Verhoef G, Dyer MJ, Ben Yehuda D, Patti C, Canales M, et al. A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. Haematologica. 2018;103(8):1351\u20138.","journal-title":"Haematologica"},{"issue":"8","key":"790_CR3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1182\/blood-2018-04-839217","volume":"132","author":"VA Chow","year":"2018","unstructured":"Chow VA, Shadman M, Gopal AK. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2018;132(8):777\u201381.","journal-title":"Blood"},{"issue":"26","key":"790_CR4","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"1","key":"790_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30928-2","volume":"19","author":"R Stirrups","year":"2018","unstructured":"Stirrups R. CAR T-cell therapy in refractory large B-cell lymphoma. Lancet Oncol. 2018;19(1):e19.","journal-title":"Lancet Oncol"},{"key":"790_CR6","doi-asserted-by":"publisher","unstructured":"Pan J, Niu Q, Deng B, Liu S, Wu T, Gao Z, et al. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia. 2019.\u00a0\nhttps:\/\/doi.org\/10.1038\/s41375-019-0488-7\n\n.","DOI":"10.1038\/s41375-019-0488-7"},{"issue":"2","key":"790_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood-2018-04-848044","volume":"133","author":"S Kusumoto","year":"2019","unstructured":"Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2019;133(2):137\u201346.","journal-title":"Blood"},{"issue":"1","key":"790_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s12185-009-0359-5","volume":"90","author":"S Kusumoto","year":"2009","unstructured":"Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009;90(1):13\u201323.","journal-title":"Int J Hematol"},{"issue":"5","key":"790_CR9","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/cid\/civ344","volume":"61","author":"S Kusumoto","year":"2015","unstructured":"Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Takasaki H, et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study. Clin Infect Dis. 2015;61(5):719\u201329.","journal-title":"Clin Infect Dis"},{"issue":"21","key":"790_CR10","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.4254\/wjh.v7.i21.2344","volume":"7","author":"Y Tsutsumi","year":"2015","unstructured":"Tsutsumi Y, Yamamoto Y, Ito S, Ohigashi H, Shiratori S, Naruse H, et al. Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol. 2015;7(21):2344\u201351.","journal-title":"World J Hepatol"},{"issue":"26","key":"790_CR11","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.3748\/wjg.v25.i26.3299","volume":"25","author":"C Sagnelli","year":"2019","unstructured":"Sagnelli C, Pisaturo M, Calo F, Martini S, Sagnelli E, Coppola N. Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention. World J Gastroenterol. 2019;25(26):3299\u2013312.","journal-title":"World J Gastroenterol"},{"issue":"12","key":"790_CR12","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.cmi.2017.06.023","volume":"23","author":"L Sarmati","year":"2017","unstructured":"Sarmati L, Andreoni M, Antonelli G, Arcese W, Bruno R, Coppola N, et al. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. Clin Microbiol Infect. 2017;23(12):935\u201340.","journal-title":"Clin Microbiol Infect"},{"key":"790_CR13","doi-asserted-by":"publisher","first-page":"204062071984158","DOI":"10.1177\/2040620719841581","volume":"10","author":"JC Chavez","year":"2019","unstructured":"Chavez JC, Bachmeier C, Kharfan-Dabaja MA. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol. 2019;10:2040620719841581.","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"790_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1200\/JCO.18.01457","volume":"37","author":"CA Jacobson","year":"2019","unstructured":"Jacobson CA. CD19 chimeric antigen receptor therapy for refractory aggressive B-cell lymphoma. J Clin Oncol. 2019;37(4):328\u201335.","journal-title":"J Clin Oncol"},{"issue":"3","key":"790_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jcv.2013.03.010","volume":"57","author":"HJ Dong","year":"2013","unstructured":"Dong HJ, Ni LN, Sheng GF, Song HL, Xu JZ, Ling Y. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis. J Clin Virol. 2013;57(3):209\u201314.","journal-title":"J Clin Virol"},{"issue":"16","key":"790_CR16","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1016\/j.ejca.2013.07.006","volume":"49","author":"SJ Kim","year":"2013","unstructured":"Kim SJ, Hsu C, Song YQ, Tay K, Hong XN, Cao J, et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia lymphoma study group. Eur J Cancer. 2013;49(16):3486\u201396.","journal-title":"Eur J Cancer"},{"issue":"26","key":"790_CR17","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1182\/blood.2019000888","volume":"133","author":"Paolo Strati","year":"2019","unstructured":"Strati P, Nastoupil LJ, Fayad LE, Samaniego F, Adkins S, Neelapu SS. Safety of CAR T-Cell Therapy in Patients with B-Cell Lymphoma and Chronic Hepatitis B or C Virus Infection. Blood. 2019;133(26):2800\u20132802.","journal-title":"Blood"},{"issue":"2","key":"790_CR18","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398.","journal-title":"J Hepatol"},{"issue":"1","key":"790_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","volume":"148","author":"KR Reddy","year":"2015","unstructured":"Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association I. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215\u20139 quiz e16\u20137.","journal-title":"Gastroenterology"},{"issue":"23","key":"790_CR20","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1001\/jama.2014.15704","volume":"312","author":"H Huang","year":"2014","unstructured":"Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. 2014;312(23):2521\u201330.","journal-title":"JAMA"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0790-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0790-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0790-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:45:58Z","timestamp":1601055958000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0790-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["790"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0790-y","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"31 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Medical Ethics Committee of the Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (TJ-IRB20160310). The patient gave her written informed consent in accordance with the Declaration of Helsinki. This study was registered at  as ChiCTR-OPN-16008526.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors obtained consent from the participant to publish and report the individual\u2019s patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"315"}}